Home > Neurology > ECTRIMS 2021 > Neuromyelitis Optica Spectrum Disorder (NMOSD) > Eculizumab, satralizumab, or inebilizumab for NMOSD?

Eculizumab, satralizumab, or inebilizumab for NMOSD?

Presented By
Prof. Dean Wingerchuk, Mayo Clinic Phoenix/Scottsdale, AZ, USA
Conference
ECTRIMS 2021
Trial
Phase 3, N-MOmentum, PREVENT, SAkuraStar, SAkuraSky
An indirect comparison analysis suggests that eculizumab is more effective than satralizumab and inebilizumab at lowering the risk of relapse in adults with neuromyelitis optica spectrum disorder (NMOSD) who are positive for aquaporin-4 protein autoantibodies (AQP4-IgG+). Not only was eculizumab superior to the other 2 agents with regard to time to first relapse, but superiority was observed both as a monotherapy and in combination with immunosuppressive treatments (ISTs), such as mycophenolate, azathioprine, or glucocorticoids [1,2]. Prof. Dean Wingerchuk (Mayo Clinic Phoenix/Scottsdale, AZ, USA) explained that given the absence of any head-to-head studies, his team conducted an indirect comparison based on published studies up to September 2020 from controlled trials testing eculizumab, satralizumab, and inebilizumab individually. He als...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on